ACP
ALXN

Aviance Capital Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Aviance Capital Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,574
Closed -$1.02M – 262
2021
Q2 		$1.02M Sell
5,574
-115
-2% -$19.7K 0.18% 139
2021
Q1 		$870K Buy
5,689
+634
+13% +$98.1K 0.17% 153
2020
Q4 		$790K Buy
5,055
+55
+1% +$7.07K 0.16% 145
2020
Q3 		$572K Buy
5,000
+336
+7% +$36.2K 0.13% 157
2020
Q2 		$523K Buy
+4,664
New +$495K 0.13% 160

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Aviance Capital Partners's ALXN Position: Q3 2021 in Review

Aviance Capital Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 5,574 shares — an estimated $1.02M sold.

Aviance Capital Partners first reported a position in ALXN in Q2 2020 and held it in 5 quarters. The position peaked at $1.02M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Aviance Capital Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Aviance Capital Partners sold 5,574 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.02M.
  • Aviance Capital Partners first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Aviance Capital Partners's Alexion Pharmaceuticals position peaked at $1.02M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Aviance Capital Partners's 13F filing for Q3 2021, filed 12 Nov 2021.